Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer

This single-arm pilot study (NCT03329937) evaluated neoadjuvant niraparib antitumor activity and safety in patients with localized HER2-negative, BRCA-mutated breast cancer. Twenty-one patients received niraparib 200 mg once daily in 28-day cycles. After 2 cycles, tumor response (≥30% reduction from...

Descripción completa

Detalles Bibliográficos
Autores principales: Spring, Laura M., Han, Hyo, Liu, Minetta C., Hamilton, Erika, Irie, Hanna, Santa-Maria, Cesar A., Reeves, James, Pan, Peng, Shan, Ming, Tang, Yongqiang, Graham, Julie R., Hazard, Sebastien, Ellisen, Leif W., Isakoff, Steven J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2022
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9402431/
https://www.ncbi.nlm.nih.gov/pubmed/35788722
http://dx.doi.org/10.1038/s43018-022-00400-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9402431/
https://www.ncbi.nlm.nih.gov/pubmed/35788722
http://dx.doi.org/10.1038/s43018-022-00400-2

Ejemplares similares